AstraZeneca Full-Year And Q4 2016 Results

AstraZeneca press release ---- AstraZeneca PLC released its Full-Year and Q4 2016 Results on February 2, 2017. According to the results, the fall in Product Sales primarily reflected the entry of Crestor generic medicines in the US; Crestor represents the last anticipated blockbuster3 patent expiry, ahead of significant late-stage pipeline news flow. Good progress on cost control in the year, reflecting the evolving shape of the business: Reported and Core R&D cost growth of 2% to $5,890m and 5% to $5,631m, respectively, including the absorption of the R&D costs of Acerta Pharma and ZS Pharma -- Reported and Core SG&A costs declined by 12% to $9,413m and by 9% to $8,169m, respectively. Reported EPS increased by 9% in the year to $2.77, reflecting a revaluation of acquisition-related liabilities. A 5% fall in Core EPS was driven by a corresponding rate of decline in Total Revenue. A second interim dividend of $1.90 per share has been declared, bringing the dividend for the full year to $2.80 per share. The Board reaffirms its commitment to the Company's progressive dividend policy. For more in depth information on AstraZeneca Full-Year and Q4 2016 results click on the picture below to read the entire report.